JAK Inhibition Decreases the Autoimmune Burden in Down Syndrome

    December 2024 in “ eLife ”
    Angela L. Rachubinski, Elizabeth Wallace, Emily Gurnee … Joaquı́n M. Espinosa
    Studysummary This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on elifesciences.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Janus Kinase Inhibitors for Alopecia Areata Journal of the American Academy of Dermatology · 2023
    2. Janus Kinase Inhibition in Down Syndrome: Two Cases of Therapeutic Benefit for Alopecia Areata JAAD case reports · 2019